- Roussel Uclaf is selling its offices in the Boulevard des Invalides in Paris, France. The move is in keeping with the company's decision to base its offices in Romainville. The offices are being acquired by the regional council of Ile de France for 815 million French francs ($154.8 million). Meantime, Roussel, together with parent company Hoechst, is reportedly negotiating to acquire a pharmaceuticals company in the USA, where it only has a 1% market share of the ethical pharmaceuticals market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze